Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 147,026 | 108,833 | 127,392 | 98,052 | 108,309 |
| Cost of Goods | 21,280 | 17,533 | 12,051 | 10,987 | 9,914 |
| Gross Profit | 125,746 | 91,300 | 115,341 | 87,065 | 98,395 |
| Operating Expenses | 242,387 | 257,180 | 237,441 | 233,149 | 247,266 |
| Operating Income | -116,361 | -165,347 | -122,049 | -145,097 | -147,957 |
| Interest Expense | 15,960 | 15,847 | 17,328 | 17,665 | 15,375 |
| Other Income | 1,581 | 10,965 | 12,485 | 3,763 | 4,236 |
| Pre-tax Income | -130,740 | -170,229 | -126,892 | -158,999 | -159,096 |
| Income Tax | 858 | 455 | -3,702 | 650 | 732 |
| Net Income Continuous | -131,598 | -170,684 | -123,190 | -159,649 | -159,828 |
| Net Income | $-131,598 | $-170,684 | $-123,190 | $-159,649 | $-159,828 |
| EPS Basic Total Ops | -1.52 | -2.03 | -1.44 | -2.23 | -2.25 |
| EPS Basic Continuous Ops | -1.52 | -2.03 | -1.44 | -2.23 | -2.25 |
| EPS Diluted Total Ops | -1.52 | -2.03 | -1.44 | -2.23 | -2.25 |
| EPS Diluted Continuous Ops | -1.52 | -2.03 | -1.44 | -2.23 | -2.25 |
| EPS Diluted Before Non-Recurring Items | -1.52 | -2.03 | -1.52 | N/A | N/A |
| EBITDA(a) | $-110,446 | $-160,258 | $-117,779 | $-140,587 | $-145,815 |